VERICI DX PLC (VRCI) — Investor Presentation

Investor webinar replay

Replay transcript excerpt

Afternoon, ladies and gentlemen, welcome to the VERICI DX Investor Presentation. Situated on the right hand corner of your screen. Just simply type in your questions at any time and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions, and we'll publish those where it's appropriate to do so. Before we begin, we would like to submit the following poll. And if you could give that your kind attention, I'm sure the company would be most grateful. I'd now like to hand over to CEO, Sarah Barrington. Good afternoon. Thank you, everybody. Appreciate the time. Let me just flip through. This is a progress report, and we will also have a financial section on the results, that were issued, earlier in June, for the year end. Okay. So what I'd like to do is just give you a an update. Obviously, the company is in its pivotal year, moving from just a pure play r and d company over to a commercial company. And that's, reflected, in the launch of Trutivia. That was at the beginning of the year. And we'll cover, some of those points and some of the feedback that we've got. Obviously, as previously noted, we are using an early adopter program, for that initial rollout. The benefits being that, firstly, we can have KOL development. That means that the clinicians that are using it in their sites will be able to be out in the marketplace talking to other clinicians as you recall. Your best credibility is clinician to clinician. So that will be a very practical way forward. Also for us, it enables us to understand how this gets rolled out both commercially, how it sits with within the clinic, how clinicians view it and I'll go through that feedback and also how you get into repeat order...